DDInter686 DDInter1376
A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Etacrynic acid {u} (Compound) treats {v} (Disease) hypertension
Etacrynic acid {u} (Compound) binds {v} (Gene) SLC12A1
Etacrynic acid {u} (Compound) upregulates {v} (Gene) CTSL
Etacrynic acid {u} (Compound) palliates {v} (Disease) chronic kidney failure
Etacrynic acid {u} (Compound) is included by {v} (Pharmacologic Class) Increased Diuresis at Loop of Henle
Etacrynic acid {u} (Compound) downregulates {v} (Gene) PLK1
Etacrynic acid {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Etacrynic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Oxytetracycline
Etacrynic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Minocycline
Etacrynic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pramlintide
Etacrynic acid (Compound) treats hypertension (Disease)
Etacrynic acid (Compound) binds SLC12A1 (Gene)
Etacrynic acid (Compound) upregulates CTSL (Gene)
Etacrynic acid (Compound) palliates chronic kidney failure (Disease)
Etacrynic acid (Compound) is included by Increased Diuresis at Loop of Henle (Pharmacologic Class)
Etacrynic acid (Compound) downregulates PLK1 (Gene)
Etacrynic acid (Compound) causes Hypoglycaemia (Side Effect)
Etacrynic acid may cause a minor interaction that can limit clinical effects when taken with Oxytetracycline
Etacrynic acid may cause a minor interaction that can limit clinical effects when taken with Minocycline
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide